Navigation Links
Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Date:11/11/2011

DURHAM, N.C., Nov. 11, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the American Society of Nephrology's (ASN) Kidney Week 2011 Annual Meeting being held November 8-13, 2011 in Philadelphia, PA.  

V. Ram Peddi, MD, Transplant Nephrologist and Director of Kidney Transplant Research at California Pacific Medical Center, will present data from Chimerix's Phase 1/2 trial evaluating CMX001 in transplant patients with BK virus (BKV) infection.  The poster presentation, entitled "CMX001 Was Well-Tolerated and Without Nephrotoxicity in Renal Transplant and Hematopoietic Stem Cell Transplant Recipients with BK Virus Infection in a Prospective, Randomized, Double-Blind Study," is part of the "Late-Breaking Clinical Trials Poster" session and begins at 10:00 am on Saturday, November 12 at the Philadelphia Convention Center.

"In the Phase 1/2 trial, CMX001 was generally safe and well tolerated when administered to renal transplant (RT) and hematopoietic stem cell transplant (HSCT) recipients," stated Wendy Painter, MD, MPH, Chief Medical Officer of Chimerix, Inc.  "Importantly, no signs of nephrotoxicity were seen following five weekly oral doses of 40 mg and the pharmacokinetics of CMX001 and cidofovir were similar between kidney transplant and bone marrow transplant recipients."  These findings are consistent with results from other CMX001 clinical trials and based on Chimerix's experience with subjects treated under emergency INDs.

CMX001 is being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, pre-emption and treatment of double-stranded DNA (dsDNA) viruses, including herpesviruses and adenoviruses, and as a potential biodefense countermeasure in the event of a smallpox release.  Data from an ongoing, placebo-controlled Phase 2 clinical trial
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
2. Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
3. Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract
4. Chimerix to Present at Two Upcoming Investor Conferences
5. Chimerix Awarded BARDA Contract for Advanced Development of Broad Spectrum Antiviral CMX001 as Medical Countermeasure Against Smallpox
6. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
7. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
8. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. Chimerix to Present at Upcoming Investor Conferences
11. Chimerix Initiates Phase 1 Study of CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Milpitas, Calif. (PRWEB) , ... August 31, 2015 ... ... earlier this year to bring together supply chain risk management and resiliency practitioners ... collaborate, develop and share best practices, and be recognized for their innovations and ...
(Date:8/31/2015)... 31, 2015 Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ... Biomedical Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... The Mexico Biomedical Sensors market is estimated at $0.20 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:8/31/2015)... , Aug. 31, 2015  RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... announced that the 30-day review period following the ... for ocular indications with the U.S. Food and ... is now active. Logo -  ...
(Date:8/31/2015)... STOCKHOLM , Aug. 31, 2015 Trimb ... an agreement to acquire YouMedical Group BV ("YouMedical"), a ... YouMedical has total annual sales of approximately EUR 16 ... categories. "Our ambition is to build ... an important step toward that goal. YouMedical gives us ...
Breaking Biology Technology:Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 2Global Supply Chain Resiliency Council Announces Incorporation and Web Site Launch 3Mexico Biomedical Sensors Market Report 2015-2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4
... we just escaped January a notoriously depressing month ... and dank weather thats no surprise. In fact, ... week ago) was the most depressing day of the ... psychological burden because of the challenges they face, their ...
... for presentation times at the Midwest Venture Summit on May ... will be selecting only a handful of presenters out ... , ,Applicants will be reviewed by a panel of investors ... consider the products that each company is producing and developing, ...
... W.M. Keck Foundation of Los Angeles has given ... how stem-cell cultures remain able to develop any other type ... scientist James Thomson was the first to grow ... are given some impetus to form other kinds of cells ...
Cached Biology Technology:Post-January, tech entrepreneurs have reasons to be depressed 2Post-January, tech entrepreneurs have reasons to be depressed 3Post-January, tech entrepreneurs have reasons to be depressed 4Follow the money 2Follow the money 3
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/5/2015)... 5, 2015 According to a ... Market by Software, Services, Vertical (BFSI, Airport, IT & Telecom, ... Global Forecast to 2020", published by MarketsandMarkets, defines and ... into various segments. The global PIAM Market is estimated ... Million by 2019, at a CAGR of 14.9 % ...
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... Global Rainmakers, Inc., an intellectual property holding company ... has exited its "stealth" mode and is prepared to ... cutting-edge biometric security offerings. , During the past four ... dollars to develop and deploy a series of core--but ...
... Oct. 27, 2009 UT Southwestern Medical Center patient ... receive the newest generation of a mechanical device designed to ... awaits a heart transplant. Called a left-ventricular assist device ... pump blood throughout the body. For Mr. LeBlanc, it will ...
... discovered the pivotal role that volcanoes played in a ... ironically, these volcanoes first caused global warming -- by ... When they stopped erupting, Earth,s climate was thrown ... discovery underscores the importance of carbon in Earth,s climate ...
Cached Biology News:Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3UT Southwestern patient first in North Texas to receive newest-generation heart failure device 2UT Southwestern patient first in North Texas to receive newest-generation heart failure device 3Volcanoes played pivotal role in ancient ice age, mass extinction 2Volcanoes played pivotal role in ancient ice age, mass extinction 3
4-Hydroxy-3-nitrophenylacetyl hapten is conjugated to SGG (Sheep gamma globulin) lysine through amide bonds. This product is homologous to NP-BSA....
RAT ANTI MOUSE F4/80 ANTIGEN:BIOTIN Immunogen: Thioglycollate stimulated peritoneal macrophages from C57/BL mice...
RABBIT ANTI PARATHION...
Recombinant Rhesus Monkey IFN-Alpha...
Biology Products: